行情

EYEG

EYEG

Eyegate制药
NASDAQ

实时行情|Nasdaq Last Sale

3.360
+0.050
+1.51%
盘后: 3.410 +0.05 +1.49% 17:57 10/18 EDT
开盘
3.345
昨收
3.310
最高
3.450
最低
3.310
成交量
3,625
成交额
--
52周最高
9.60
52周最低
2.250
市值
1,023.13万
市盈率(TTM)
-0.0938
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EYEG 新闻

  • 沪指震荡微跌 高层密集表态加大开放
  • 新浪财经.1小时前
  • GoPro:昙花一现只隔了3年
  • 创事记.2小时前
  • 韩国10月前20天出口锐减近20% 或连续11个月下滑
  • 新浪财经综合.2小时前
  • 因沙特石油设施遇袭 这些产油国9月超额完成交易
  • 中国新闻网.2小时前

更多

所属板块

制药
-0.90%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

EYEG 简况

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
展开

Webull提供Eyegate Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。